‘No Final Diagnosis’ Yet for Ill COVID-19 Vaccine Recipient: AstraZeneca

‘No Final Diagnosis’ Yet for Ill COVID-19 Vaccine Recipient: AstraZeneca
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York City, N.Y. on April 8, 2019. Brendan McDermid/Reuters
|Updated:

AstraZeneca said on Sept. 9 that there is “no final diagnosis” for the single COVID-19 vaccine trial participant who has developed a “potentially unexplained” illness, causing the company to temporarily halt for the second time its late-stage Phase Three trial for its vaccine candidate.

A spokesperson for the company said in a statement Wednesday that reports claiming to be made by AstraZeneca’s CEO, Pascal Soriot, saying that he confirmed the participant presented adverse symptoms are “incorrect.”

Isabel van Brugen
Isabel van Brugen
Reporter
Isabel van Brugen is an award-winning journalist. She holds a master's in newspaper journalism from City, University of London.
twitter
Related Topics